Home Stories Landmark Agreement Signed to Prevent Malaria in Pregnancy in sub-Saharan Africa

Landmark Agreement Signed to Prevent Malaria in Pregnancy in sub-Saharan Africa

UNITAID, Jhpiego and ISI Global logos

Madrid, Spain — An ambitious effort has been launched to prevent malaria in pregnancy in communities in sub-Saharan Africa. This innovative initiative will complement existing antenatal care services and increase pregnant women’s opportunities to access care under a grant agreement signed today by Unitaid and Jhpiego.

Unitaid is investing US $50 million to ensure that pregnant women in malaria-affected countries in sub-Saharan Africa have access to a preventive therapy for malaria known as “intermittent preventive treatment in pregnancy” or IPTp. The five-year project, to be implemented by Jhpiego, will increase IPTp coverage and expand antenatal care attendance in four African countries—the Democratic Republic of Congo, Madagascar, Mozambique and Nigeria.

Three people sitting at a table, while one signs a paper
S.A.R. la Infanta Doña Cristina de Borbón, representing ISGlobal; Lelio Marmora, Unitaid’s Executive Director; and Jhpiego’s Richard Lamporte at the signing ceremony in Madrid.

The project—also known as “Transforming IPT for Optimal Pregnancy” (TIPTOP)—will increase IPTp coverage through community-level distribution of quality-assured sulfadoxine-pyramithimine (the medicine used for IPT). Jhpiego has partnered with the Barcelona Institute for Global Health (ISGlobal), which will lead the research and evaluation components of the project. The two organizations will also collaborate with the World Health Organization (WHO) and Medicines for Malaria Venture to achieve the desired results.

Young boy
The Transforming IPT for Optimal Pregnancy project (TIPTOP) seeks to provide pregnant women with greater access to preventative therapy for malaria in sub-Saharan Africa. Photo by Jhpiego/Karen Kasmauski.

This community-based IPTp approach, which will augment and complement existing antenatal care services by reaching 400,000 pregnant women and their babies, will also produce the evidence needed to update WHO’s policy on IPTp.

In areas with high malaria transmission, pregnant women and young children are especially vulnerable to malaria infection and death. Although malaria is preventable and treatable, an estimated 429,000 people died from the disease in 2015, according to WHO. Moreover, malaria during pregnancy can lead to a number of negative consequences, including low birth-weight for babies and even still births. In some cases, malaria can be fatal for the mother. In 2015, IPTp coverage rates remained at just 31 percent in 20 African countries.

The Unitaid-funded TIPTOP project plans to engage community health workers to increase IPTp delivery and demand to ensure there are no missed opportunities for pregnant women to receive this lifesaving medicine either in the community or through the antenatal services.

“By accelerating access to this critical, lifesaving preventive therapy, we are hoping to avert further unnecessary deaths from malaria,” said Lelio Marmora, Unitaid’s Executive Director. “Unitaid continues to advance on all fronts by developing innovative tools to fight malaria and insecticide resistance.”

Dr. Leslie Mancuso, Jhpiego’s CEO and President, said the TIPTOP project offers an exciting opportunity to demonstrate an innovative approach to address pregnant women’s needs and stop malaria in pregnancy. “Preventing malaria in pregnancy and reducing malaria-related deaths is achievable—and this partnership will go a long way toward reaching those goals,” she said.

About Jhpiego

Jhpiego, an international nonprofit health organization affiliated with the Johns Hopkins University, has worked for 45 years to empower frontline health workers by designing and implementing effective, low-cost, hands-on solutions to strengthen the delivery of health care services for women and their families.

About ISGlobal

The Barcelona Institute for Global Health (ISGlobal), the result of an innovative alliance between the “la Caixa” Foundation, academic institutions and government bodies, was set up to contribute to the work undertaken by the international community to address the challenges of health in a globalized world.

About Unitaid

Unitaid is an international organization that invests in new ways to prevent, diagnose and treat HIV/AIDS, hepatitis C, tuberculosis and malaria more quickly, more cheaply and more effectively. It accelerates access to innovation so critical health products reach people who most need them. Unitaid’s work allows large-scale introduction of health products through funding by the Global Fund, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and governments.

For more information go to www.jhpiego.org or contact Kristin Vibbert at 1-484-888-0277.